CIB vs EWBC

The deterministic health profile is critical, highlighted by a Piotroski F-Score of 0/9, indicating severe deterioration in financial fundamentals. While the stock has shown impressive long-term price appreciation and maintains a strong ROE of 16.96%, current growth metrics are catastrophic with YoY revenue down 80.10% and earnings down 72.30%. The stock is currently trading at $71.51, which is significantly above its growth-based intrinsic value of $55.30 and the analyst target price of $63.76. Despite an attractive dividend yield, the fundamental collapse outweighs the valuation appeal.

EWBC presents a dichotomy between strong fundamental growth and concerning internal signals. The Piotroski F-Score of 4/9 indicates stable but not strong financial health, while the current price of $119.09 aligns closely with the Graham Number of $117.71, suggesting the stock is fairly valued from a defensive standpoint. While YoY revenue and earnings growth exceed 21% and the P/E ratio is significantly lower than the sector average, heavy insider selling and a very weak technical trend score (10/100) offset the bullish growth metrics.